Andere talen Affimed N.V.

Aandelen

AFMD

NL0015001ZQ0

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,33 ^USD	-0,37%		+9,22%	-14,72%

01/04	AFFIMED N.V. : Wells Fargo Securities geeft koopadvies	ZM
01/04	AFFIMED N.V. : HC Wainwright herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	24/04
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed Reports 2023 Financial Results and Operational Progress	28/03
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	21/03
Affimed N : Form 6-K	11/03
Affimed Announces 1-for-10 Reverse Stock Split	06/03
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	09/01
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	08/01
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	08/01
Affimed Announces Leadership Change and Organizational Restructuring	08/01
Affimed N.V. Announces CEO Changes	08/01
Affimed N.V. Announces Management Changes	08/01
Sector Update: Health Care Stocks Mixed Late Afternoon	03/01
Sector Update: Health Care Stocks Gain in Afternoon Trading	03/01
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	03/01
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	03/01
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	03/01
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index	15/12
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Affimed N.V.

Aandelen

AFMD

NL0015001ZQ0

Andere talen

Filters